Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income towards Parent Company (2019 - 2025)

Historic Income towards Parent Company for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Income towards Parent Company rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13432.12%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
  • As of Q3 2025, Keros Therapeutics' Income towards Parent Company stood at -$7.3 million, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Income towards Parent Company peaked at $148.5 million during Q1 2025, and registered a low of -$53.0 million during Q3 2024.
  • In the last 5 years, Keros Therapeutics' Income towards Parent Company had a median value of -$29.7 million in 2022 and averaged -$21.6 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 32821.33% in 2022, then skyrocketed by 44432.2% in 2025.
  • Keros Therapeutics' Income towards Parent Company (Quarter) stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then tumbled by 56.32% to -$46.5 million in 2023, then grew by 0.92% to -$46.0 million in 2024, then soared by 84.18% to -$7.3 million in 2025.
  • Its Income towards Parent Company was -$7.3 million in Q3 2025, compared to -$30.7 million in Q2 2025 and $148.5 million in Q1 2025.